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ABSTRACT
Objective Eosinophils reside in the colonic mucosa
and increase significantly during disease. Although a
number of studies have suggested that eosinophils
contribute to the pathogenesis of GI inflammation, the
expanding scope of eosinophil-mediated activities
indicate that they also regulate local immune responses
and modulate tissue inflammation. We sought to define
the impact of eosinophils that respond to acute phases
of colitis in mice.
Design Acute colitis was induced in mice by
administration of dextran sulfate sodium, 2,4,6-
trinitrobenzenesulfonic acid or oxazolone to C57BL/6J
(control) or eosinophil deficient (PHIL) mice. Eosinophils
were also depleted from mice using antibodies against
interleukin (IL)-5 or by grafting bone marrow from PHIL
mice into control mice. Colon tissues were collected and
analysed by immunohistochemistry, flow cytometry and
reverse transcription PCR; lipids were analysed by mass
spectroscopy.
Results Eosinophil-deficient mice developed
significantly more severe colitis, and their colon tissues
contained a greater number of neutrophils, than
controls. This compensatory increase in neutrophils was
accompanied by increased levels of the chemokines
CXCL1 and CXCL2, which attract neutrophils. Lipidomic
analyses of colonic tissue from eosinophil-deficient mice
identified a deficiency in the docosahexaenoic acid-
derived anti-inflammatory mediator 10, 17-
dihydroxydocosahexaenoic acid (diHDoHE), namely
protectin D1 (PD1). Administration of an exogenous
PD1-isomer (10S, 17S-DiHDoHE) reduced the severity of
colitis in eosinophil-deficient mice. The PD1-isomer also
attenuated neutrophil infiltration and reduced levels of
tumour necrosis factor-α, IL-1β, IL-6 and inducible NO-
synthase in colons of mice. Finally, in vitro assays
identified a direct inhibitory effect of PD1-isomer on
neutrophil transepithelial migration.
Conclusions Eosinophils exert a protective effect in
acute mouse colitis, via production of anti-inflammatory
lipid mediators.
INTRODUCTION
Eosinophils synthesise and release a broad range of
biologically active mediators, including antimicro-
bial, proremodelling or anti-inflammatory asso-
ciated factors (reviewed in1 2). An increasing body
of evidence suggests that eosinophils play a primary
role in a number of diseases such as asthma3–5 and
eosinophilic GI diseases.6–8 In these diseases, eosi-
nophils increase within the mucosal surfaces where
they may participate in processes that often contrib-
ute to tissue damage9 10 and/or remodelling,11
either way leading to eventual organ dysfunction.
Acute inflammatory/immune reparative responses
are necessary self-limited processes that participate
in maintaining host health and tissue function.
Mucosal surfaces use and amplify acute restorative
anti-inflammatory activities through a number of
mechanisms including anti-inflammatory lipid
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Significance of this study
What is already known on this subject?
▸ IBD is a disease characterised by increased
numbers of eosinophils.
▸ The exact role of eosinophils during the onset
of inflammation and in chronic disease remains
unclear.
What are the new findings?
▸ In the absence of eosinophils, mice succumb to
a greater colonic inflammation during acute
experimental models of colitis.
▸ Eosinophil-deficient mice develop an exuberant
and compensatory neutrophilic inflammation of
the colon, accompanied by greater increases in
levels of proinflammatory molecules.
▸ Eosinophil-deficient mice have diminished
levels of arachidonate-15-lipoxygenase, the
lipid biosynthetic enzyme, and the proresolving
lipid mediator protectin D1 during acute colonic
inflammation, and administration of protectin
D1-isomer to eosinophil-deficient mice
attenuates inflammatory indices of colitis,
including neutrophilic infiltration.
How might it impact on clinical practice in
the foreseeable future?
▸ Since eosinophils are normal residents of the
colonic mucosa, further studies are necessary
to determine eosinophil’s role in health and
disease. Protective factors released or regulated
by eosinophils may be beneficial to colonic
health.
Inflammatory bowel disease
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mediator synthesis.12 13 In this regard, omega-3 polyunsaturated
fatty acid (PUFA)-derived resolvins and protectins are potent
anti-inflammatory lipid mediators. For example, mice ingesting
chow rich in endogenous omega-3 fatty acids have less severe
colitis.14 By contrast, increased consumption of dietary proin-
flammatory omega-6 PUFA correlates with an increase in IBD
incidence.15 16 Thus, dietary omega-3 fatty acid-derived anti-
inflammatory molecules have emerged as potent options for
therapeutic intervention.17–20 Docosahexaenoic acid (DHA), an
omega-3 PUFA abundant in fish oils, is converted to hydroxydo-
cosahexaenoic acids (HDoHE), by enzymatic oxidation.
Protectin D1 (PD1) (10,17- dihydroxydocosahexaenoic acid
(DiHDoHE)) is biosynthesised by 15-lipoxygenase (LOX) in
humans and 12/15-LOX in mice, and present in inflamed
tissues.21–24 Recent reports show that both human and mouse
eosinophils express high levels of leucocyte-type 15-LOX and
12/15-LOX, respectively, and are capable of producing PD1
when activated in vitro.24 25 Other cells with the potential to
express 12/15-LOX include dendritic cells, tissue-resident
macrophage, mast cells and epithelial cells.21 While the presence
of the enzyme is necessary, it is not always sufficient for PD1
biosynthesis, as expression may be regulated by environmental
factors, such as cytokines or cell differentiation/activation
states.21 Administration of exogenous PD1 to mouse models of
inflammation protects tissues from inflammatory damage,
expediting phagocytic resolution of acute peritonitis and retinal
injury models, attenuating inflammation and airway hyper-
responsiveness in mouse asthma models, while mouse eosino-
phils contribute to the resolution of acute peritonitis in a
12/15-LOX-dependent manner.12 22–24 26 To date, the receptor
and, therefore, cellular target for PD1 has not been identified.
Expression of these lipid mediators, association with colonic
eosinophils and their role in resolution responses during colonic
inflammation is incompletely understood. The aim of our study
was to determine the role(s) of eosinophils in mouse models of
acute colitis. Here we provide evidence for a novel protective
role of eosinophils and concurrently show that this protection
also correlates with the induced levels of 12/15-LOX-derived
anti-inflammatory lipid mediators. Results from these studies
have broad implications on potential therapeutic options for
patients with IBD.
MATERIALS AND METHODS
Mice
All studies were performed with female C57BL/6J mice (wild
type, WT) and PHIL.27 Eosinophil depletion studies were com-
pleted using a monoclonal antibody specific for interleukin-5
(TRFK-5; Cayman Chemical, Ann Arbor, Michigan, USA). Age
and sex-matched C57BL/6J littermate mice were used as con-
trols. The University of Colorado and Mayo Clinic Arizona
IACUC approved studies.
Dextran sodium sulfate, 2,4,6-trinitrobenzenesulfonic acid
and Oxazolone-induced colitis
Colitis was induced by administering dextran sodium sulfate
(DSS) (2.5%–3.5%(w/v)) 36 000–50 000 kDa; (MP Biomedicals,
Santa Ana, California, USA), trinitrobenzenesulfonic acid
(TNBS) or oxazolone (OXA) (Sigma, St Louis, Missouri, USA) to
10-week old mice for up to 6–8 days. Daily assessments of
disease activity index (DAI) (ie, weight loss, stool consistency and
faecal blood) and postnecropsy colon lengths were measured as
previously described.28
In some studies, the commercially available DHA-derived
PD1 isomer (10S, 17S-diHDoHE)23 29 (hereafter referred to as
PD1-isomer) (0.05 mg/kg) (Cayman Chemical, Ann Arbor,
Michigan, USA) was administered to mice.
Generation of bone marrow chimeric mice
Bone marrow chimeric mice were generated by transferring iso-
lated bone marrow from PHIL (PHIL->WT) or WT
(WT->WT) donor mice into the retro-orbital plexus of subleth-
ally irradiated WTrecipients, as described previously.30
Tissue processing and histological analysis
Whole length colons were removed, processed and a global
inflammatory score was developed from H&E stained sections
modified to account for area of tissue affected from that
described previously.28
Immunohistochemical assessment of eosinophil,
myeloperoxidase or F4/80 cellular inflammation
Eosinophils were localised in mouse and human tissues
(Institutional Review Board approved) by eosinophil major basic
protein-1 (MBP-1) and eosinophil peroxidase immunohisto-
chemistry as previously described.11 31 Neutrophils were loca-
lised in mouse tissues by myeloperoxidase (MPO)
immunohistochemistry. Macrophage and other F4/80+ cells
were localised in mouse tissues by F4/80 immunohistochemistry.
In situ hybridisation assessment of CXCL1 production
Formalin-fixed paraffin-embedded sections were subjected to
in situ hybridisation with probes targeted to the CXCL1 mRNA
as per manufacturer’s recommendations (Advanced Cell
Diagnostics, Hayward, California, USA). Slight modifications
are detailed in online supplementary methods. Probes directed
towards Ubc and DapB were used as positive and negative con-
trols, respectively.
Colonic lamina propria and bone marrow leucocyte isolation
for flow cytometry
Leucocytes were isolated from colonic mucosa by collagenase
digestion as previously described.11 30 32 Bone marrow cells
were isolated from femurs and tibias.33 Viable single cell suspen-
sions were subjected to flow cytometric analysis as previously
described.32
RNA isolation and real-time RT-PCR
Taqman gene expression assays (Applied Biosystems, Foster City,
California, USA) were performed on whole colon RNA, pro-
cessed as previously described.11 Data were normalised to 18S
and calculated as relative quantity (2−ΔΔCt, where Ct is cycle
threshold for each sample).
Colon lipidomic analysis
Colon tissues were harvested and processed for liquid chroma-
tography tandem mass spectrometry (LC-MS/MS) based lipido-
mics analyses as previously described.12 MS/MS analyses were
conducted in negative ion mode, and fatty acid metabolites were
identified and quantified by multiple reaction monitoring.
Cell culture and in vitro transmigration assay
Caco-2 human intestinal epithelial cells were cultured and poly-
morphonuclear (PMN) cell transmigration towards a gradient of
100 nM Formyl–Methionyl–Leucyl–Phenylalanine (FMLP;
Sigma, St Louis, Missouri, USA) was performed as previously
described.34 35 PMNs were added in the presence of 0.2 or
20 nM of PD1-isomer or vehicle alone.
Inflammatory bowel disease
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Statistical analysis
Statistical analyses of data outcomes were performed by Student
t test, one-way analysis of variance or Log-rank (Mantel–Cox)
test (conservative) survival curve where appropriate. Data are
expressed as means±SEM. A p value of ≤0.05 was considered as
statistical significance although in some cases higher levels of
significance are noted and described in the figure legends
where applicable: *†p≤0.05, ††p≤0.01, †††p≤0.001.
Further detail can be found in online supplementary materials
and methods.
RESULTS
Protective role for eosinophils in three models of acute colitis
Analysis of WT-mice and human tissues identified eosinophils as a
significant component of the acute inflammatory response in
experimental DSS-colitis and ulcerative colitis (figure 1A–C).
Additionally, analysis of molecular responses identified that
eosinophilic chemokines were significantly increased in experi-
mental DSS-colitis (figure 1D). Except for the absence of eosino-
phils, the normal colonic mucosa of WT-mice and eosinophil-less
(PHIL)-mice appeared the same (figure 2A). We induced
DSS-colitis and monitored disease activity to determine the impact
of eosinophils in acute experimental colitis. Upon harvest, colonic
length was found to be significantly shorter (48.4 vs 53.8 mm,
PHIL-DSS vs WT-DSS; p<0.001), and in congruence, tissue
injury was significantly greater in PHIL-DSS compared with
WT-DSS challenged mice, as evidenced by histological scoring
of ulceration, oedema and leucocytic infiltration (19.5 vs 12.1,
PHIL vs WT; p<0.001) (figure 2B, C). As shown in figure 2D,
PHIL-mice experienced a greater mortality compared with
WT-mice (PHIL-DSS—29% death vs WT-DSS—0% at 7 days).
Further studies, with lower DSS concentrations, determined that
PHIL-DSS mice developed significantly greater weight loss than
WT-DSS mice in a time-dependent fashion (8.2% greater loss
day 6, p<0.001; 5.9% greater loss day 7, p<0.01; 6.4% greater
loss day 8, p<0.05; figure 2E). PHIL-DSS mice also had a higher
DAI compared with WT-DSS mice (4.4 points greater day 6,
p<0.001; 2.5 points greater day 7, p<0.01; 3 points greater
day 8, p<0.05; figure 2F).
We next induced TNBS-colitis and monitored disease activity
as described above. Results from these studies were remarkably
similar to those found in DSS-colitis. PHIL-mice compared with
WT-mice, experienced a greater rate of weight loss (7% greater
loss day 2, p<0.05; 7% greater loss day 3, p<0.05), signifi-
cantly shorter colon length (50 mm vs 61 mm, PHIL-TNBS vs
WT-TNBS; p<0.001) and greater histological measure of
disease (9.8 vs 3.5, PHIL-TNBS vs WT-TNBS; p<0.01) (see
online supplementary figure S1).
In a third method of experimentally inducible colitis, WTand
PHIL mice were treated with OXA-colitis. The death rate was
89% in PHIL-OXA and 20% in WT-OXA mice at day 4 postin-
stillation, p<0.0005 vs WT-OXA. No vehicle-treated mice of
either genotype died. At 3 days postinstillation, maximum
weight loss was observed (WT-OXA 88.29±2.3% vs PHIL-OXA
78.833±3.9% (p=0.07)). By 4 days postinstillation, most PHIL
mice had died. Thus, consistent with findings in DSS and TNBS
models of colitis, PHIL mice were more susceptible than their
WT littermate counterparts and did not survive the induction of
colitis using the OXA methodology.
We used two other methods, antibody targeting and bone
marrow depletion, to address eosinophils’ role in colitis as
Figure 1 Eosinophilic inflammation in acute colitis. (A) H&E, and major basic protein immunohistochemistry on mouse colons following dextran
sodium sulfate (DSS)-colitis. (B) Eosinophil peroxidase immunohistochemistry on human colons from normal and ulcerative colitis subjects. (C) Wild
type whole mouse colon analysis by flow cytometry for infiltrating myeloid leucocytes. (D) Colon mRNA analysis for eosinophil-associated
chemokines CCL11, CCL24 and CCL5. Scale bars represent 100 and 50 μM, respectively. Data are expressed as means±SEM of 3–7 individual mice
per group and represent >3-independent experimental repeats following 6 days of colitis. *p≤0.05.
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described below. The first model used the IL-5-depleting mono-
clonal antibody (TRFK-5) to reduce the eosinophil colonic
population by 50% in WT-mice (see online supplementary
figure S2). Induction of DSS-colitis in TRFK-5-treated WT-mice
(WTTRFK-5), led to similarly increased colonic inflammation as
observed in PHIL-mice. WTTRFK-5 mice displayed increased DAI
relative to WT-controls (1.4 points greater on day 4, p<0.01
and 2.4 points greater on day 6, p<0.05; figure 3A) and shorter
colon lengths (52.4 vs 56.7 mm; p<0.01; WTTRFK-5-DSS vs
WTVeh-DSS; figure 3B). Histological scores revealed a signifi-
cantly greater degree of tissue injury in WTTRFK-5 eosinophil-
depleted mice compared with WT-control animals (13.8 vs 7.5,
p<0.05; figure 3C). The second model of eosinophil depletion
used was bone marrow engraftment of WT recipient mice with
donor marrow from PHIL-mice (see online supplementary
figure S3). In this series of experiments, we induced DSS-colitis
in bone marrow chimeric mice. WT-recipient animals receiving
PHIL marrow (PHIL->WT) with DSS-induced colitis uniquely
displayed an eosinophil deficiency that did not occur in
DSS-induced WT-recipients of WT-marrow (WT->WT) or
DSS-induced WT-mice (see online supplementary figure S3A,
B). Similar to both PHIL and TRFK-5-treated mice,
DSS-induced colitis in eosinophil-less PHIL->WT chimera-mice
was significantly greater than that observed in eosinophil-
sufficient WT->WT chimeras (figure 3D), including significant
changes in DAI (1.8 points greater day 3, p<0.01; 1.9 points
greater day 4, p<0.05; 1 point greater day 5, p<0.05;
1.6 points greater day 6, p<0.001 and greater colon shortening
(50.0 mm vs 60.5 mm; PHIL->WT vs WT->WT,
respectively, p<0.05) (figure 3E). Comparisons of histology
scores from colons of DSS-treated mice also confirmed that
PHIL and PHIL->WT chimeras displayed the same increased
inflammatory phenotype relative to WT and WT->WT chimeras
(figure 3F).
Taken together, induction of colitis in three models of eosino-
phil reduction demonstrates that disease-ameliorating effects
dynamically track with the presence of eosinophils.
Neutrophils are the predominant infiltrate in
eosinophil-deficient DSS-treated mice
We assessed the inflammatory cell infiltrate of colonic lamina
propria in DSS-treated mice to define changes in the tissue
milieu that occurred in the absence of eosinophils. While PHIL
colonic mucosae were virtually devoid of eosinophils compared
with 50% eosinophils in DSS-treated WT-mice (WT-control vs
WT-DSS, p<0.05) (figure 4A, B), there were no differences
observed in the frequencies of macrophages and dendritic cells
(figure 4C–F). Quantitated immunohistochemistry for F4/80
positive cells per high-powered field also showed no difference
when comparing PHIL-DSS with WT-DSS mouse colons (55.99
±6.4 vs 49.95±2.4; p=0.74). By contrast, as shown in figure 4,
the higher inflammatory responses occurring in the colons of
DSS-treated PHIL-mice (relative to DSS-treated WT-mice)
resulted in a further differential increase in colonic neutrophils
((90%) 13.5×103 vs (42%) 7.2×103, PHIL-DSS vs WT-DSS;
p<0.05). There were very few neutrophils observed in normal
PHIL and WT colons (0.4×103 vs 0.3×103, PHIL vs WT; n.s.).
These data demonstrated that a lack of tissue eosinophils
appears to promote the accumulation of colonic neutrophils
during inflammation (figure 4A, B). Immunohistochemistry for
MPO on colonic tissue sections was used as an additional
method of validation. Quantification determined a significant
Figure 2 Protective role for eosinophils in acute colitis. Dextran sodium sulfate (DSS) or water-vehicle was administered to wild type (WT)-mice
and PHIL-mice. (A) Representative H&E-stained sections of colons from WT-DSS and PHIL-DSS mice (100× magnification), (B) Colon lengths were
assessed upon sacrifice and (C) A histological scoring tool combining injury and inflammation was applied to H&E-stained sections following 6 days
of colitis. (D) Kaplan–meier survival curve comparing PHIL-DSS and WT-DSS littermates. (E) Colitis-induced weight loss as a percentage of day zero
and (F) overall disease activity index calculated in PHIL compared with WT controls following 8 days of colitis. Data are expressed as means±SEM of
15 individual control mice and seven individual mice per DSS group and represent >3-independent experimental repeats. *p≤0.05, **p≤0.01,
***p≤0.001.
Inflammatory bowel disease
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increase in the number of MPO-positive cells per high-powered
field in PHIL-DSS versus WT-DSS colons (124 vs 97, p<0.05)
(see online supplementary figure S4A). Congruent with this
observation, a significant increase in colonic neutrophils during
DSS-colitis was also observed following TRFK-5 or bone
marrow chimeric eosinophil depletion (see online supplemen-
tary figures S1 and S2) and in PHIL mice following TNBS
colitis (see online supplementary figure S4B).
Consistent with this finding is the molecular characterisation
of the colonic inflammatory microenvironment. While the
proinflammatory cytokines tumour necrosis factor (TNF)-α,
interleukin (IL)-1β and IL-6 were all elevated in the colons of
DSS-treated WT-mice, the level of each proinflammatory cyto-
kine was further augmented in the colons of DSS-treated
PHIL-mice (figure 5A–C). By contrast, type-2 cytokines typical
of Th2 responses (ie, IL-4, IL-5 and IL-13) were not increased
in PHIL or WT-mice (figure 5D–F). Enhanced neutrophilic
inflammation occurring in DSS-treated PHIL colons compared
with WT-mice was accompanied by a differential increase in
neutrophil-associated chemokines CXCL1 (mKC) and CXCL2
(macrophage inflammatory protein (MIP)-2β), likely a finding
secondary to the increased state of mucosal inflammation, and
not directly related to eosinophil-specific effects on production
(figure 6A, B). In situ hybridisation analysis for CXCL1 found
the cellular sources for this chemokine in mouse colon sections
from PHIL-DSS and WT-DSS mice to be very similar. Here we
found that both epithelial cells as well as lamina propria infil-
trating leucocytes produce this chemokine in equal abundance
(see online supplementary figure S5). We also measured NOS2
(iNOS) expression in the colonic mucosa as a confirmatory
metric of the enhanced neutrophilic inflammation occurring in
DSS-treated PHIL-versus-WT-mice. Similar to what was
observed with other neutrophil-associated events occurring in
DSS-treated PHIL-versus-WT-mouse colons, the level of iNOS
expression was significantly higher in PHIL-mouse colons rela-
tive to the increase observed in DSS-treated WT-mice (figure
6C). Previously published work has provided a link between the
myeloid immune system, particularly neutrophils, and lipid
mediator synthesis. We thus measured the lipid oxidation
enzymes prostaglandin-endoperoxide synthase 1 (PTGS1),
PTGS2, arachidonate 5-lipoxygenase (ALOX5), ALOX12 and
ALOX15 in the colons of eosinophil null, neutrophil-
predominant DSS-treated PHIL-versus-WT-mice (figure 6D–I).
A significant inhibition of ALOX15 induction was observed in
PHIL-DSS versus WT-DSS colons (figure 6H).
Eosinophil depletion is associated with decreased 12/
15-LOX derived lipid metabolites
Since our finding that lipid oxidation enzyme production was
altered, most specifically ALOX15 (figure 6H), and lipid media-
tors generated at local tissue sites are influenced by and in turn
influence accumulation of select leucocyte populations in inflam-
mation,36 we reasoned that eosinophils might influence the lipid
mediator profile of DSS-colitis. LC-MS/MS-based lipidomic ana-
lyses performed on colonic tissue from PHIL and WT-mice
revealed that loss of eosinophils in colons of PHIL-mice was
associated with a significant decline in lipid molecules derived
from 12/15-LOX dependent pathways, congruent with our
Figure 3 Antibody depletion or myeloablation of eosinophils exacerbates acute colitis. Mice were depleted of eosinophils by antibody mediated
interleukin-5 diminution (anti-TRFK-5), induced with dextran sodium sulfate (DSS)-colitis and (A) disease activity, (B) colonic length and (C) histology
scores of H&E-stained colon tissues were reported. Bone marrow chimera was performed between PHIL-donors and wild type (WT)-recipients
(PHIL->WT) and between WT-donors and WT-recipients (WT->WT) as controls. Age and sex matched PHIL-mice and WT-mice were maintained as
controls. Mice were induced with colitis and (D) disease activity, (E) colonic length and (F) histology scores of H&E-stained colon tissues were
reported. Data are expressed as means±SEM of 3-7 individual mice per group and represent 2-independent experimental repeats following 6 days of
colitis. *†p≤0.05, ††p≤0.01, †††p≤0.001 PHIL->WT-DSS-versus-WT->WT-DSS.
Inflammatory bowel disease
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observation of inhibited ALOX15 induction. In particular, colon
levels of eosinophil-associated anti-inflammatory PD124 37 were
virtually absent in healthy-PHIL-mice (0.6 ng/g-colon) and
DSS-treated PHIL-mice (1 ng/g-colon) relative to eosinophil suf-
ficient healthy (3 ng/g-colon) and DSS-treated (11 ng/g-colon)
WT-mice (PHIL-DSS vs WT-DSS; p<0.05) (figure 7-inset). No
difference in levels of the PD1 precursor DHA was observed in
either PHIL or WT colons prior to, or following, the induction
of colitis. However, 17-hydroxy-DHA, a marker of DHA utilisa-
tion, was significantly decreased in PHIL-colons prior to and
following induction of colitis (p<0.001). Levels of lipid media-
tors derived from the other major metabolic networks linked
Figure 4 Inflammatory infiltrate in eosinophil null mucosa is predominated by neutrophils. Whole colon flow cytometry analysis for infiltrating
myeloid leucocytes in wild type (WT)-colons and PHIL-colons in dextran sodium sulfate (DSS)-colitis. Derivation and quantification of relative
proportions of (A and B) neutrophils and eosinophils, (C and D) macrophage and (E and F) dendritic cell infiltrates comparing WT-DSS with
PHIL-DSS-colitis. Data are expressed as means±SEM of seven individual mice per group and represent >3-independent experimental repeats
following 6 days of colitis. **p≤0.01, Wild Type versus PHIL.
Inflammatory bowel disease
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with cyclo-oxygenase (COX) and/or 5-LOX were not different
in PHIL and WT healthy or DSS-treated colons. Congruent
with our finding of increased neutrophils in inflamed
eosinophil-deficient colons, a significant increase in the
neutrophil-associated chemokine LTB4 was observed (figure 7).
Exogenous administration of PD1-isomer rescues PHIL-mice
from colitis and diminishes neutrophil chemotaxis and
inflammation
Administration of PD1-isomer to DSS-treated PHIL-mice
resulted in significant improvement in colonic inflammation
(figure 8). Specifically, PD1-isomer treatment of PHIL-mice
resulted in significant improvement in colon shortening (69.5
mm vs 60.6 mm vs 52.8 mm, Control PHIL vs. PD1-isomer-
treated PHIL vs vehicle-treated PHIL, p<0.01) and histological
scores (9.4 vs 16.5, PD1-isomer-treated PHIL vs vehicle-treated
PHIL, p<0.01) (figure 8A, B). Representative photomicrographs
of colonic mucosa from PD1-isomer-treated mice revealed
improvements in epithelial cell loss, inflammatory infiltrates,
and architectural disruption (figure 8C). Consistent with these
findings, proinflammatory molecules, including TNF-α, IL-1β
and IL-6 decreased significantly (figure 8D).
PD1-isomer add-back also led to a significant decrease in neu-
trophilic inflammation in DSS-treated PHIL-mice (figure 8E), as
well as a decrease in neutrophil-specific chemokines CXCL-1/
KC and CXCL-2/MIP2-α and proinflammatory NOS2 (figure
8D). Ex vivo chemotaxis studies further substantiated the anti-
inflammatory effects of PD1-isomer leading to a concentration-
dependent decrease in PMN chemotaxis across intestinal epithe-
lial monolayers compared with control PMNs (figure 8G). Such
findings identify PD1/PD1-isomers as a prominent molecular
signature that attenuates neutrophil accumulation during
ongoing colonic inflammation.
DISCUSSION
Although eosinophil accumulation in tissues of patients with
IBD has been described, the specific and unique contributions
of eosinophils to IBD has yet to be clearly delineated.2 6 8 38
Here, we demonstrate a protective role for eosinophils during
mouse colitis. We show that the physical, histological and
molecular features of acute colonic inflammation are signifi-
cantly increased without these granulocytes. Our data demon-
strates acute colitis in eosinophil-competent mice correlates with
biosynthesis of anti-inflammatory derivatives of omega-3 fatty
acids, including PD1, a molecule known to dampen neutrophil
influx and proinflammatory cytokine production.23 The enzyme
necessary for PD1 synthesis, 15-LOX was not induced in
PHIL-mice and, thus, PD1 was barely detectable in PHIL-mice
Figure 5 Proinflammatory and type-2 cytokine expression profile in PHIL-mice during acute colitis. mRNA was isolated from whole colons and
assessed by Taqman technologies. (A–C) Major acute proinflammatory cytokines tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 as well
as (D–F) Type-2 cytokines IL-4, IL-5 and IL-13 were measured. Data are expressed as means±SEM of 7–10 individual mice per group and represent
2-independent experimental repeats following 6 days of colitis. *p≤0.05, **p≤0.01, ***p≤0.001 versus genotype matched water controls.
†p≤0.05, ††p≤0.01, †††p≤0.001 versus wild type-dextran sodium sulfate (DSS).
Inflammatory bowel disease
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at baseline or during colitis suggesting an important role for
these leucocytes in PD1 synthesis in this myeloid predominant
acute experimental colitis model. Bypassing the deficiency in the
15-LOX enzyme, exogenous administration of PD1-isomer to
eosinophil-deficient mice following colonic injury markedly atte-
nuated weight loss, colon shortening, histological indices of
injury and inflammation, PMN infiltration and proinflammatory
cytokine production including TNF-α, IL-1β, IL-6 and inducible
nitric oxide. These findings suggest a role for acute-phase-
responding eosinophils, either directly or indirectly, in the
resolution of early inflammatory responses, possibly through
alterations in gene expression and leucocyte recruitment, such
as that mediated by the 12/15-LOX-derived lipid mediator
PD1/PD1-isomers.
To date, the role of eosinophils during IBD has remained
elusive. A number of studies suggest an end-stage destructive
role(s) for eosinophils in the pathogenesis of gut inflammation
in addition to other mucosal organs.10 39 For instance, eosino-
phil granule protein null mice were relatively protected from
colitis indicating a pathological role for these proteins.10 39–41
Figure 6 Chemokine, iNOS and lipid oxygenation enzyme expression profile in PHIL-mice during acute colitis. mRNA was isolated from whole
colons and assessed by Taqman technologies. (A–C) Neutrophil-associated transcripts CXCL1/KC, CXCL2 and NOS2 were assessed. (D–H) Lipid
oxygenation enzymes critical for lipid mediator biosynthesis PTGS1, PTGS2, ALOX5, ALOX12 and ALOX15 were also measured. Data are expressed as
means±SEM of 7–10 individual mice per group and represent 2-independent experimental repeats following 6 days of colitis. *p≤0.05, **p≤0.01,
***p≤0.001 versus genotype-matched water controls. †p≤0.05, ††p≤0.01, †††p≤0.001 versus wild type-dextran sodium sulfate (DSS).
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The emerging dual role for eosinophils in contributing to host
health and to inflammation is a fascinating one. Eosinophils
have been reported as important for the maintenance of host
health in the retention of memory plasma cells to the bone
marrow.42 They are also important for the maintenance of
microbial homeostasis of commensal organisms in the intestines
during health by retaining IgA-producing plasma cells in peyer’s
patches.43 It is important to note that eosinophil-deficient mice
are not devoid of IgA, however, as other mechanisms of IgA
production were maintained. Both these studies implicate eosi-
nophils as a primary source for the critical plasma cell chemo-
kine, APRIL. In the setting of acute peritoneal inflammation,
eosinophils have also been demonstrated as protective sentinels,
producing anti-inflammatory lipids including PD1, promoting
the rate of resolution.24 Experimental models of colonic inflam-
mation, such as the IL-10−/− mouse present with significant
colonic eosinophilia prior to and during disease.44 In this
model, the absence of IL-4 and, thus, eosinophils resulted in
diminished disease and led the authors to suggest important role
(s) for eosinophils in the initiation of colitis. However, IL-4
mediates significant influences on a number of other potential
pathogenic effector cells. In light of our findings, one could
speculate eosinophils’ increase prior to the onset of inflamma-
tion, as observed in the IL-10−/− model, may be an early
attempt to dampen inflammation, potentially via mechanisms
including the production of anti-inflammatory lipid mediators,
among others, for example, PD1. It is important to keep in
context that eosinophils may play a role, but are not the sole
mediators in the maintenance of intestinal health and homeosta-
sis. It appears that eosinophils may react to acute insults in
attempt to resolve and restore intestinal health.
Clinical studies have identified increased numbers of colonic
eosinophils in disease states and a reduction following treatment
providing circumstantial evidence for a pathogenic role for eosi-
nophils in patients.45 Contrasting with this, others have found
an increase in eosinophils during disease remission.46 However,
studies have not addressed the impact of eosinophils in the
acute/early phase of colitis induction, including whether the
baseline population of these granulocytes may offer host benefits
as a part of innate host defence. Recent review speculates that
eosinophils may mediate host health by antimicrobial and tissue
repair functions.2 When these cells are chronically present in
excess however, they may indeed participate in a deleterious
manner towards organ dysfunction.
Figure 7 12/15-lipoxygenase (12/15-LOX) lipid derivative deficiency in colitis in PHIL-mice. Whole mouse colons from dextran sodium sulfate
(DSS)-colitis and water control wild type (WT)-mice and PHIL-mice were assessed by LC-MS/MS-based mediator lipidomics following 6 days of colitis.
Arachidonic acid (AA)-derived, eicosapentaenoic acid-derived and docosahexaenoic acid (DHA)-derived products were quantified by LC-MS/MS, and
multiple reaction monitoring. Levels of 12/15-LOX products are boxed in black or blue and 12/15-LOX biosynthetic end products with statistically
significant differences are in blue shaded boxes. Data are expressed as means±SEM of 3-H2O and 6-DSS individual mice. *p≤0.05, **p≤0.01,
***p≤0.001 DSS versus genotype-matched water controls. ††p≤0.01, †††p≤0.001 PHIL-DSS versus WT-DSS.
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Two previous studies have addressed the impact of eosinophils
on the development of colitis.9 47 Comparison of those results
with findings shown here, yielded different conclusions, thus
demonstrating the complexity of studies in mouse models of
disease. For example, results from two models of eosinophil
deficiency (PHIL and ΔdblGATA) at two locations (USA and
Brazil) suggested that the loss of eosinophils leads to the ameli-
oration of colitis.9 47 Potential factors that explain these conflict-
ing results include technical aspects of experimental colitis
induction, institutional differences including dietary source and
composition, age of mice and variability in eosinophil-deficient
strains. For example, Ahrens et al studied PHIL-mice at younger
ages than our study and measured histology and colon length as
the primary readouts. Vieira et al examined the ΔdblGATA
mouse, deficient in basophils, in addition to eosinophils,48 and
used a higher concentration of DSS than our studies (4% vs
2.5%). Additionally, the dietary availability and ratio of the gen-
erally considered proinflammatory omega-6 and anti-
inflammatory omega-3 precursors of potent lipid mediators in
different mouse chow will play a critical role in the balance
between inflammation and its resolution. We suggest that these
experimental differences are significant and contribute to the
disparity in our findings. More importantly, we propose that
this likely reflects the multifaceted role of eosinophils in disease
initially contributing anti-inflammatory activities following acute
provocation and then proinflammatory effects in chronic set-
tings. Our ongoing studies of eosinophil deficiency in a variety
of environmental settings (eg, barrier facilities vs conventional
Figure 8 Protectin D1 (PD1)-isomer (PD1-i) treatment attenuates colitis in PHIL-mice via attenuation of neutrophil migration. PHIL- dextran sodium
sulfate (DSS)-colitis mice were treated with PD1-isomer or vehicle via intraperitoneal injection 0.05 mg/kg daily throughout the course of colitis
which lasted 6 days. Upon sacrifice, colons were excised and (A) colon length measured. (B) Injury, inflammatory and total histology scores were
assessed and (C) representative H&E-stained sections from PHIL-DSS-mice treated with PD1-isomer or vehicle (100× magnification). (D)
Proinflammatory cytokine and neutrophil-associated chemokine mRNA production was examined in PD1-isomer versus vehicle-treated
PHIL-DSS-mice. (E and F) Flow cytometric analysis of lamina propria infiltrates for neutrophil percent and absolute number comparing PD1-isomer
with vehicle-treated PHIL-DSS-controls. Data are expressed as means±SEM of 3–7 individual mice per group, and represent 2 independent
experimental repeats. (G) In vitro examination of the effects of PD1-isomer on Formyl–Methionyl–Leucyl–Phenylalanine-induced neutrophil-colon
epithelial monolayer (Caco-2) transmigration; dose-dependence and time-dependence. Data are expressed as means±SEM of three individual donors
and three independent experimental repeats. *p≤0.05, **p≤0.01 0.2 nM PD1 versus controls. ††p≤0.01, †††p≤0.001 20 nM PD1-isomer versus
controls.
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housing venues)49 provide an additional confounding perspec-
tive; the rapidly responsive microbiome and/or exposure to
environmental toxicants (eg, endotoxins) present in the resident
animal facilities are likely to be key issues modulating the
immune/inflammatory responses linked with eosinophils in
mouse models of disease.50 We suggest that the confounding
interinstitutional issues are a consequence of these extrinsic
modulatory events, altering the proinflammatory versus anti-
inflammatory roles of eosinophils in a given setting. It may be
possible that each, or any combination, of these factors may be
necessary to stimulate the eosinophil population to act in a regu-
latory manner. Thus, both conclusions may be correct, and the
specific circumstances surrounding a given model and protocol
will need to be noted in future studies with the multiple
eosinophil-deficient mouse models now currently available.
Our study contributes to a growing body of basic and clinical
studies that support a role for omega-3 PUFAs and their deriva-
tives in IBD treatment. 17–20 51–53 While we do not rule out the
potential contributions of anti-inflammatory lipids derived from
COX or 5-LO biosynthesis pathways,54 we specifically see a
global deficiency in 12/15-LOX and its derived lipid mediators
in the absence of eosinophils. Moreover, we do not discount the
potential anti-inflammatory utility of AA or eicosapentaenoic
acid-derived 12/15-LOX mediated lipids, including
5,15-diHETE and 15-HEPE, however 5,15-diHETE may
potentiate PMN degranulation and thus exacerbate inflamma-
tion in this model.55 Our studies have focused on the
DHA-derived, previously established eosinophil-associated, PD1
molecule.24 37 The data reported here suggest a link between
eosinophil activities and the levels of the DHA-derived PD1
family of lipid mediators present in the initial stages of colonic
inflammation, an attempt by the host to limit colonic inflamma-
tion. However, in addition to eosinophils, 12/15-LOX-derived
biosynthesis of PD1 and its isomers may occur through other
cells present during DSS-colitis, such as tissue-resident macro-
phages, dendritic cells, mast cells as well as epithelial cells.21
Our experiments do not rule out these other cell types as poten-
tial contributors of PD1/PD1-isomers. Nonetheless, it is note-
worthy that no differences were observed in the frequencies of
these other cells between colitic PHIL and control mice, suggest-
ing the critical role, specifically for the increased eosinophil
infiltrate in either directly or indirectly producing or inducing
15-LOX, and the proresolving lipid mediator PD1/PD1-isomers.
Thus, these findings are consistent with observations that
recruitment of eosinophils and production of PD1/PD1-isomers
are associated with reduced numbers of neutrophils in inflamed
tissue and the resolution of inflammation.22 24 The importance
of eosinophil-derived PD1/PD1-isomer expression awaits future
studies using eosinophil-specific 12/15-LOX knockout mice gen-
erated by using 12/15-LOXflox/flox animals crossed with
eosinophil-specific Cre-expressing mice.
Reconstitution studies, and in vitro modelling identify the
impact of PD1-isomer on reducing PMN inflammation in colitis
as has been demonstrated in other organ systems.23 36 56 Our
data extends these findings by showing that proinflammatory
gene expression (TNF-α, IL-1β, IL-6, nitric oxide, CXCL1 and
CXCL2) associated with PMN recruitment in colonic tissues
decreases following PD1-isomer treatment. This reduction in
proinflammatory cytokines and PMN infiltration, mediated, in
part, by pharmacological reconstitution with PD1-isomers, may
be an effective approach in the prevention and maintenance of
remission in patients with IBD.
In summary, the present study highlights a critical role for
eosinophils in regulating inflammatory tone during acute
experimental mouse colitis. Mechanistically, we identify that the
omega-3 PUFA-derived lipid mediator, PD1/PD1-isomer specif-
ically limits colon PMN infiltration. Interestingly, complete abla-
tion of neutrophil recruitment in animal models of colitis is
itself deleterious, and may suggest that a balance between eosi-
nophils and neutrophils may be necessary for resolution of
inflammation.57 58 These findings support a potentially protect-
ive role for resident eosinophils in mouse colitis and, thus, chal-
lenge the paradigm for a solely proinflammatory role in human
disease. We speculate that in certain circumstances, the increased
presence of eosinophils in early stages of mucosal inflammation
may not necessarily be an indicator of disease, but rather a host
response, fostering mucosal healing and a pathway to return to
homoeostasis (figure 1). Thus, future translational studies
linking numbers of eosinophils in a given patient with observed
histopathology and clinical manifestation of disease are neces-
sary to test our hypotheses.
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